Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution - NEC
- Sub-Industry: N/A
- Symbol: NYSE:NVRO
- CUSIP: N/A
- Web: www.nevro.com
Capitalization:- Market Cap: $2.47 billion
- Outstanding Shares: 29,443,000
Average Prices:- 50 Day Moving Avg: $83.73
- 200 Day Moving Avg: $85.18
- 52 Week Range: $65.82 - $106.93
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -933.44
- P/E Growth: -2.89
Sales & Book Value:- Annual Revenue: $277.91 million
- Price / Sales: 8.90
- Book Value: $8.18 per share
- Price / Book: 10.27
Profitability:- EBIDTA: ($22,570,000.00)
- Net Margins: -14.33%
- Return on Equity: -16.25%
- Return on Assets: -9.43%
Debt:- Debt-to-Equity Ratio: 0.59%
- Current Ratio: 11.07%
- Quick Ratio: 8.73%
Misc:- Average Volume: 619,598 shs.
- Beta: -0.68
- Short Ratio: 7.44
Frequently Asked Questions for Nevro Corp. (NYSE:NVRO)
What is Nevro Corp.'s stock symbol?
Nevro Corp. trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro Corp.'s earnings last quarter?
Nevro Corp. (NYSE:NVRO) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.11. The firm earned $78.02 million during the quarter, compared to the consensus estimate of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The business's revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.31) EPS. View Nevro Corp.'s Earnings History.
When will Nevro Corp. make its next earnings announcement?
Where is Nevro Corp.'s stock going? Where will Nevro Corp.'s stock price be in 2017?
6 analysts have issued twelve-month target prices for Nevro Corp.'s shares. Their forecasts range from $85.00 to $120.00. On average, they anticipate Nevro Corp.'s share price to reach $101.33 in the next year. View Analyst Ratings for Nevro Corp..
What are analysts saying about Nevro Corp. stock?
Here are some recent quotes from research analysts about Nevro Corp. stock:
- 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (8/11/2017)
- 2. Northland Securities analysts commented, "The widely awaited release of Boston Scientific's ACCELERATE Study data on the Q4 call today, was a downer. Strangely enough, the company stated on its call that it "would continue enrolling patients in the trial, expects enrollment to finish by end of FY17, and data release by mid-2018." Suffice it to say, the anti-climax will be perceived as something being off in the ACCELERATE Study, hence being positive for Nevro."The analyst speculated that something is off in the ACCELERATE study, causing a delay in datarelease. Here are some thoughts / questions:Is Boston Sci increasing the sample size in the trial ?Was there a sub-group analysis done and investigators realized that the bellcurve on lead placements was not on T8 - T10 locations, hence pain relief was sub-optimal? Will there now be more anatomical placement on T8 - T10 with its HF arm? In essence, is Boston Sci converging on Nevro's "secret sauce" (2/2/2017)
Who are some of Nevro Corp.'s key competitors?
Some companies that are related to Nevro Corp. include Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), NuVasive (NUVA), LivaNova PLC (LIVN), Neogen Corporation (NEOG), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), MiMedx Group (MDXG), CONMED Corporation (CNMD), OraSure Technologies (OSUR), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), Asante Solutions (PUMP), Intersect ENT (XENT) and Orthofix International N.V. (OFIX).
Who are Nevro Corp.'s key executives?
Nevro Corp.'s management team includes the folowing people:
- Rami Elghandour, President, Chief Executive Officer
- Andrew H. Galligan, Chief Financial Officer
- Patrick Schmitz, Vice President - Operations
- Michael Enxing, Vice President of Sales
- Douglas A. Alleavitch, Vice President - Quality and Operations
- Christopher Christoforou, Vice President - Research and Development
- Ali Behbahani M.D., Independent Director
- Lisa D. Earnhardt, Independent Director
- Frank M. Fischer, Independent Director
- Wilfred E. Jaeger M.D., Independent Director
Who owns Nevro Corp. stock?
Nevro Corp.'s stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.74%), BlackRock Inc. (6.10%), Franklin Resources Inc. (5.26%), Janus Henderson Group PLC (4.83%), Alliancebernstein L.P. (4.27%) and FMR LLC (4.19%). Company insiders that own Nevro Corp. stock include Andre Walker, Andrew H Galligan, Brad Vale, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro Corp..
Who sold Nevro Corp. stock? Who is selling Nevro Corp. stock?
Nevro Corp.'s stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Columbus Circle Investors, Voya Investment Management LLC, Goldman Sachs Group Inc., American Century Companies Inc., Summit Partners Public Asset Management LLC, Russell Investments Group Ltd. and Macquarie Group Ltd.. Company insiders that have sold Nevro Corp. stock in the last year include Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Insider Buying and Selling for Nevro Corp..
Who bought Nevro Corp. stock? Who is buying Nevro Corp. stock?
Nevro Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, Wells Fargo & Company MN, Westfield Capital Management Co. LP, BlackRock Inc., Zevenbergen Capital Investments LLC, Tekla Capital Management LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Nevro Corp..
How do I buy Nevro Corp. stock?
Shares of Nevro Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nevro Corp.'s stock price today?
One share of Nevro Corp. stock can currently be purchased for approximately $84.01.
MarketBeat Community Rating for Nevro Corp. (NYSE NVRO)MarketBeat's community ratings are surveys of what our community members think about Nevro Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Nevro Corp. (NYSE:NVRO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.83) |
| Consensus Price Target: | $101.33 (20.62% upside) |
Analysts' Ratings History for Nevro Corp. (NYSE:NVRO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/8/2017 | Northland Securities | Reiterated Rating | Buy | $96.00 | High |  |
| 8/8/2017 | Morgan Stanley | Boost Price Target | Overweight | $87.00 -> $95.00 | Medium | |
| 7/5/2017 | Canaccord Genuity | Reiterated Rating | Buy | $120.00 | High | |
| 7/3/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight | $102.00 | Low | |
| 5/14/2017 | B. Riley | Downgrade | Neutral | $85.00 | Low | |
| 2/24/2017 | Leerink Swann | Boost Price Target | Outperform | $100.00 -> $110.00 | N/A | |
| 8/11/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $98.00 -> $112.00 | N/A | |
| 8/9/2016 | JMP Securities | Boost Price Target | Market Outperform | $90.00 -> $110.00 | N/A | |
| 8/9/2016 | BMO Capital Markets | Reiterated Rating | Buy | $100.00 | N/A | |
| 8/8/2016 | Bank of America Corporation | Initiated Coverage | Buy | $100.00 | N/A | |
| 7/18/2016 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 7/12/2016 | Wells Fargo & Company | Initiated Coverage | Outperform | | N/A | |
| 5/16/2016 | Sterne Agee CRT | Reiterated Rating | Buy | | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for Nevro Corp. (NYSE:NVRO)Earnings History by Quarter for Nevro Corp. (NYSE NVRO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | | | | | | | |
| 8/7/2017 | Q2 2017 | ($0.29) | ($0.40) | $77.75 million | $78.02 million | View | Listen | |
| 5/8/2017 | Q1 2017 | ($0.26) | ($0.50) | $68.71 million | $68.40 million | View | Listen | |
| 2/23/2017 | Q416 | ($0.20) | ($0.34) | $66.41 million | $70.50 million | View | N/A | |
| 11/7/2016 | Q316 | ($0.39) | ($0.14) | $58.05 million | $60.92 million | View | Listen | |
| 8/8/2016 | Q216 | ($0.47) | ($0.31) | $45.11 million | $55.40 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.65) | ($0.33) | $33.48 million | $41.65 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.56) | ($0.51) | $32.88 million | $33.10 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.75) | ($0.70) | $12.51 million | $15.40 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.89) | ($0.77) | $9.65 million | $11.40 million | View | N/A | |
| 5/11/2015 | Q1 | ($0.54) | ($0.57) | $8.20 million | $9.66 million | View | Listen | |
| 3/18/2015 | Q4 2014 | ($0.51) | ($0.59) | | $9.72 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Nevro Corp. (NYSE:NVRO)Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-0.09 EPS
Dividend History for Nevro Corp. (NYSE:NVRO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nevro Corp. (NYSE:NVRO)Insider Ownership Percentage: 12.10%
Insider Trades by Quarter for Nevro Corp. (NYSE:NVRO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/16/2017 | Wilfred E. Jaeger | Director | Sell | 79,657 | $82.74 | $6,590,820.18 | |
| 8/15/2017 | Wilfred E. Jaeger | Director | Sell | 29,665 | $82.54 | $2,448,549.10 | |
| 8/14/2017 | Andrew H. Galligan | CFO | Sell | 7,000 | $82.31 | $576,170.00 | |
| 8/14/2017 | Wilfred E. Jaeger | Director | Sell | 25,255 | $82.40 | $2,081,012.00 | |
| 5/15/2017 | Andrew H. Galligan | CFO | Sell | 7,500 | $75.30 | $564,750.00 | |
| 5/2/2017 | Michael F Demane | Director | Sell | 29,800 | $96.07 | $2,862,886.00 | |
| 5/1/2017 | Rami Elghandour | CEO | Sell | 10,000 | $95.03 | $950,300.00 | |
| 4/4/2017 | Michael Enxing | VP | Sell | 1,500 | $93.53 | $140,295.00 | |
| 4/4/2017 | Michael F Demane | Director | Sell | 22,200 | $93.39 | $2,073,258.00 | |
| 4/3/2017 | Andrew H. Galligan | CFO | Sell | 30,000 | $94.46 | $2,833,800.00 | |
| 3/6/2017 | Michael Enxing | VP | Sell | 38,500 | $91.01 | $3,503,885.00 | |
| 3/3/2017 | Wilfred E Jaeger | Director | Sell | 43,980 | $95.03 | $4,179,419.40 | |
| 1/4/2017 | Michael Enxing | VP | Sell | 1,500 | $75.88 | $113,820.00 | |
| 12/5/2016 | Michael Enxing | VP | Sell | 1,500 | $76.38 | $114,570.00 | |
| 11/15/2016 | Andrew H Galligan | CFO | Sell | 7,500 | $86.90 | $651,750.00 | |
| 10/10/2016 | Rami Elghandour | CEO | Sell | 3,000 | $100.00 | $300,000.00 | |
| 10/6/2016 | Michael F Demane | Director | Sell | 139,514 | $97.46 | $13,597,034.44 | |
| 10/4/2016 | Michael Enxing | VP | Sell | 1,500 | $99.31 | $148,965.00 | |
| 8/22/2016 | Doug Alleavitch | VP | Sell | 3,000 | $100.00 | $300,000.00 | |
| 8/22/2016 | Wilfred E Jaeger | Director | Sell | 154,840 | $97.79 | $15,141,803.60 | |
| 8/17/2016 | Wilfred E Jaeger | Director | Sell | 155,160 | $97.31 | $15,098,619.60 | |
| 8/15/2016 | Andrew H Galligan | CFO | Sell | 7,500 | $97.71 | $732,825.00 | |
| 8/10/2016 | Doug Alleavitch | VP | Sell | 2,500 | $95.00 | $237,500.00 | |
| 8/9/2016 | Michael F Demane | Director | Sell | 26,667 | $91.50 | $2,440,030.50 | |
| 8/4/2016 | Michael Enxing | VP | Sell | 1,500 | $82.06 | $123,090.00 | |
| 7/29/2016 | Doug Alleavitch | VP | Sell | 1,000 | $85.00 | $85,000.00 | |
| 7/29/2016 | Michael F Demane | Director | Sell | 13,333 | $84.00 | $1,119,972.00 | |
| 7/11/2016 | Doug Alleavitch | VP | Sell | 2,000 | $80.00 | $160,000.00 | |
| 7/11/2016 | Michael F Demane | Director | Sell | 13,333 | $79.00 | $1,053,307.00 | |
| 7/5/2016 | Michael Enxing | VP | Sell | 1,500 | $75.39 | $113,085.00 | |
| 7/1/2016 | Michael F Demane | Director | Sell | 13,333 | $74.00 | $986,642.00 | |
| 6/8/2016 | Doug Alleavitch | VP | Sell | 1,000 | $75.00 | $75,000.00 | |
| 6/8/2016 | Rami Elghandour | CEO | Sell | 7,000 | $76.59 | $536,130.00 | |
| 6/6/2016 | Michael Enxing | VP | Sell | 1,500 | $73.29 | $109,935.00 | |
| 6/2/2016 | Andre Walker | VP | Sell | 4,000 | $73.50 | $294,000.00 | |
| 6/1/2016 | Doug Alleavitch | VP | Sell | 500 | $72.00 | $36,000.00 | |
| 5/18/2016 | Wilfred E Jaeger | Director | Sell | 112,983 | $64.68 | $7,307,740.44 | |
| 5/16/2016 | Andrew H Galligan | CFO | Sell | 10,000 | $64.78 | $647,800.00 | |
| 5/16/2016 | Michael F Demane | CEO | Sell | 39,999 | $64.77 | $2,590,735.23 | |
| 5/12/2016 | Rami Elghandour | President | Sell | 7,000 | $63.93 | $447,510.00 | |
| 5/4/2016 | Michael Enxing | VP | Sell | 1,500 | $65.06 | $97,590.00 | |
| 4/4/2016 | Michael Enxing | VP | Sell | 8,767 | $61.59 | $539,959.53 | |
| 4/1/2016 | Rami Elghandour | President | Sell | 7,000 | $60.99 | $426,930.00 | |
| 1/11/2016 | Andre Walker | VP | Sell | 7,987 | $70.75 | $565,080.25 | |
| 1/4/2016 | Doug Alleavitch | VP | Sell | 2,514 | $66.47 | $167,105.58 | |
| 12/17/2015 | Andre Walker | VP | Sell | 13 | $69.00 | $897.00 | |
| 12/7/2015 | Rami Elghandour | President | Sell | 3,500 | $61.82 | $216,370.00 | |
| 12/2/2015 | Andre Walker | VP | Sell | 1,000 | $64.00 | $64,000.00 | |
| 12/1/2015 | Andre Walker | VP | Sell | 8,000 | $59.50 | $476,000.00 | |
| 11/30/2015 | Andre Walker | VP | Sell | 6,000 | $58.50 | $351,000.00 | |
| 11/30/2015 | Rami Elghandour | President | Sell | 3,500 | $60.00 | $210,000.00 | |
| 11/24/2015 | Andre Walker | VP | Sell | 1,000 | $55.00 | $55,000.00 | |
| 11/23/2015 | Andre Walker | VP | Sell | 1,000 | $54.00 | $54,000.00 | |
| 11/23/2015 | Wilfred E Jaeger | Director | Sell | 25,000 | $53.48 | $1,337,000.00 | |
| 11/18/2015 | Wilfred E Jaeger | Director | Sell | 175,000 | $52.24 | $9,142,000.00 | |
| 11/16/2015 | Michael F Demane | CEO | Sell | 26,667 | $50.52 | $1,347,216.84 | |
| 11/13/2015 | Brad Vale | Director | Buy | 2,000 | $50.76 | $101,520.00 | |
| 9/17/2015 | Andre Walker | VP | Sell | 4,000 | $50.75 | $203,000.00 | |
| 9/2/2015 | Michael F Demane | CEO | Sell | 40,001 | $45.11 | $1,804,445.11 | |
| 6/8/2015 | & Johnson Johnson | Major Shareholder | Sell | 1,010,265 | $47.94 | $48,432,104.10 | |
| 6/8/2015 | Bay City Capital Llc | Insider | Sell | 491,835 | $47.94 | $23,578,569.90 | |
| 6/8/2015 | Wilfred E Jaeger | Director | Sell | 393,468 | $47.94 | $18,862,855.92 | |
| 11/12/2014 | & Johnson Johnson | Major Shareholder | Buy | 40,000 | $18.00 | $720,000.00 | |
| 11/12/2014 | A/S Novo | Insider | Buy | 215,000 | $18.00 | $3,870,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Nevro Corp. (NYSE:NVRO)
Latest Headlines for Nevro Corp. (NYSE:NVRO)
| Source: |
|
| Date | Headline |
|---|
 | Nevro Corp. (NVRO) Expected to Post Quarterly Sales of $79.51 Million
www.americanbankingnews.com - August 18 at 3:50 AM |
| Nevro Corp. (NVRO) Director Sells $6,590,820.18 in Stock
www.americanbankingnews.com - August 16 at 7:39 PM |
| Wilfred E. Jaeger Sells 25,255 Shares of Nevro Corp. (NVRO) Stock
www.americanbankingnews.com - August 16 at 7:38 PM |
| Nevro Corp. (NVRO) Director Sells $2,448,549.10 in Stock
www.americanbankingnews.com - August 16 at 7:38 PM |
| Nevro Corp. (NVRO) CFO Sells $576,170.00 in Stock
www.americanbankingnews.com - August 16 at 1:40 PM |
 | See what the IHS Markit Score report has to say about Nevro Corp.
finance.yahoo.com - August 13 at 12:41 AM |
| IHS Markit Score Update: Drop in demand for ETFs holding Nevro Corp is a negative sign for its shares
finance.yahoo.com - August 11 at 7:07 AM |
| Edited Transcript of NVRO earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 6:21 AM |
| Nevro Corp.'s (NVRO) "Buy" Rating Reiterated at Northland Securities
www.americanbankingnews.com - August 8 at 10:14 PM |
| Investor Network: Nevro Corp. to Host Earnings Call
finance.yahoo.com - August 8 at 2:08 AM |
| Nevro Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 2:08 AM |
| Nevro reports 2Q loss
finance.yahoo.com - August 8 at 2:08 AM |
| Nevro Corp. (NYSE:NVRO) Issues Quarterly Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - August 7 at 7:27 PM |
| Should You Buy Nevro (NVRO) Ahead of Earnings?
finance.yahoo.com - August 4 at 6:30 AM |
| Nevro Corp. (NYSE:NVRO) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 9:28 AM |
| Nevro Corp. (NYSE:NVRO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - July 29 at 1:36 PM |
| Nevro Corp. (NVRO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 28 at 7:15 AM |
| Nevro to Present at the Canaccord Genuity Growth Conference
finance.yahoo.com - July 27 at 5:48 AM |
| Nevro to Report Operating Results for the Second Quarter 2017
finance.yahoo.com - July 25 at 6:18 AM |
| Reviewing Bio-Rad Laboratories (BIO) and Nevro Corp. (NVRO)
www.americanbankingnews.com - July 22 at 8:04 AM |
| Nevro Corp. (NVRO) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - July 16 at 10:50 PM |
 | Nevro Corp (NVRO) Shares Cross Above 200 DMA
www.nasdaq.com - July 14 at 7:01 AM |
 | Medical Equipment Stock Performance Review -- Nevro, EnteroMedics, Avinger, and ViewRay
www.prnewswire.com - July 13 at 7:32 AM |
| Nevro (NVRO) Surges: Stock Moves 11.4% Higher - Nasdaq
www.nasdaq.com - July 8 at 6:13 PM |
| ETFs with exposure to Nevro Corp. : July 7, 2017
finance.yahoo.com - July 8 at 1:12 PM |
| Nevro Corp. breached its 50 day moving average in a Bullish Manner : NVRO-US : July 6, 2017
finance.yahoo.com - July 7 at 7:47 AM |
| Health Care Sector Update for 07/05/2017: NVRO,MTBC,BGNE - Nasdaq
www.nasdaq.com - July 6 at 7:36 AM |
| BUZZ-U.S. STOCKS ON THE MOVE- Tesla, Diebold Nixdorf, Nevro ... - Nasdaq
www.nasdaq.com - July 6 at 7:36 AM |
| Here's Why Shares of Nevro Corp. (NVRO) Jumped Today - Nasdaq
www.nasdaq.com - July 6 at 7:36 AM |
| Here's Why Shares of Nevro Corp. (NVRO) Jumped Today
finance.yahoo.com - July 6 at 7:36 AM |
| Brokerages Anticipate Nevro Corp. (NVRO) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - July 5 at 2:12 PM |
| Canaccord Genuity Reaffirms Buy Rating for Nevro Corp. (NYSE:NVRO)
www.americanbankingnews.com - July 5 at 1:58 PM |
 | Why Nevro Corp. Is Soaring 10% Higher Today
www.fool.com - July 5 at 1:19 PM |
| Nevro Announces Preliminary Unaudited Second Quarter 2017 Revenue and Business Update - PR Newswire (press release)
www.prnewswire.com - July 5 at 9:03 AM |
| Nevro Announces Preliminary Unaudited Second Quarter 2017 Revenue and Business Update
finance.yahoo.com - July 5 at 9:03 AM |
| Nevro Corp. (NYSE:NVRO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 10:40 AM |
| Nevro Corp. (NYSE:NVRO) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - July 3 at 9:50 AM |
| ETFs with exposure to Nevro Corp. : June 26, 2017
finance.yahoo.com - June 27 at 6:47 AM |
| Nevro Corp. (NVRO) Given a $96.00 Price Target at Northland Securities
www.americanbankingnews.com - June 17 at 2:20 PM |
| ETFs with exposure to Nevro Corp. : June 16, 2017
finance.yahoo.com - June 16 at 7:55 PM |
 | Nevro (NVRO) SENZA-RCT 24-Month Outcomes Publication Selected by Neurosurgery as Top Pain Paper of the Year - StreetInsider.com
www.streetinsider.com - June 16 at 8:20 AM |
| Neurosurgery Selects the SENZA-RCT 24-Month Outcomes Publication as the Top Pain Paper of the Year
finance.yahoo.com - June 16 at 8:20 AM |
| Nevro Corp. :NVRO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 4:10 PM |
| Brokerages Expect Nevro Corp (NVRO) Will Announce Quarterly Sales of $73.83 Million
www.americanbankingnews.com - June 11 at 8:56 AM |
| Zacks: Brokerages Anticipate Nevro Corp (NVRO) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - June 9 at 2:12 PM |
| Nevro Corp (NVRO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 6 at 7:38 AM |
| Zacks Investment Research Lowers Nevro Corp (NVRO) to Sell
www.americanbankingnews.com - June 3 at 7:12 AM |
| Relative Strength Alert For Nevro
www.nasdaq.com - May 31 at 7:17 PM |
| Nevro to Present at the William Blair Growth Stock Conference
finance.yahoo.com - May 30 at 6:40 PM |
| Nevro Corp (NVRO) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - May 24 at 3:56 PM |
Nevro Corp. (NVRO) Chart for Sunday, August, 20, 2017
